Imaging blood flow and glucose metabolism using PET

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to develop a single-tracer multiparametric PET imaging solution that simultaneously assesses blood flow and glucose metabolism using 18F-fluorodeoxyglucose (FDG). The study will utilize tracer kinetic modeling to extract quantitative blood flow data from dynamic 18F-FDG PET scans. This approach is significant for understanding flow-metabolism relationships in various conditions, including ischemic cardiomyopathy and cancer. The study will involve both healthy volunteers and patients with cardiovascular diseases to evaluate the effectiveness of this imaging technique.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Inclusion Criteria for all research participants:

   * Adults (age ≥ 18 years old)
   * Ability to understand and willingness to sign an informed consent form
   * Ability to adhere to the study visit schedule and other protocol requirements.
   * Willing and able to fast for at least 6 hours before and for the duration of the scan
   * No strenuous exercise for 24 hours prior to being scanned
   * Willing to lie on the scanner bed for up to 60 minutes
   * Free of active COVID-19 symptoms
2. Inclusion Criteria for healthy volunteers only:

   • Free of history of cardiovascular, inflammatory, infections or metabolic diseases that would result in changes in normal tissue perfusion and/or metabolism.
3. Inclusion Criteria for patients with disease:

   * Patients with clinically acute or chronic conditions such as cardiovascular, cardiometabolic, or cardiopulmonary diseases, which may include but are not limited to ischemic heart disease, myocarditis, arrhythmias, heart failure, nonalcoholic fatty liver disease, COVID-related sequala, diabetes, hypertension, or renal disease that would result in changes in normal tissue perfusion and/or metabolism.

Exclusion Criteria:

Participants are not eligible if they meet ANY of the following criteria:

* Self-reported history of dysphoria or anxiety in closed spaces
* Body weight \>240 kg due to limitations of the scanner bed
* Pregnant or breast-feeding (due to risks of ionizing radiation; urine pregnancy test will be administered prior to start of each PET/CT session for all participants between 18 to 60 years old who are able to get pregnant, unless documented hysterectomy or bilateral ovarian removal is available)
* Blood glucose greater than 200 as assessed by fingerstick method before injection of 18F-FDG
* Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.
* Prisoners
* Any condition that would prevent the understanding or rendering of informed consent.
* Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.

Where it's running

• UC Davis EXPLORER Molecular Imaging Center
  Sacramento, California, United States Recruiting

Study contacts

• Principal investigator: Guobao Wang, PhD — University of California, Davis
• Study coordinator: Clinical Research Team
• Email: research-radiology-som@health.ucdavis.edu
• Phone: 916-731-9004

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease

  This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.

  Recruiting Odense University Hospital · Svendborg · NCT07878325

• Petrelintide for weight loss in people with overweight/obesity and heart disease

  This study tests whether petrelintide helps people with overweight or obesity and cardiovascular disease lose weight when added to a reduced-calorie diet and more physical activity, compared with a placebo.

  Recruiting at 3 sites Phase 3 Hoffmann-La Roche · Anniston, Alabama and 2 other locations · NCT07843472

• VERVE-102 for adults with or at high risk for heart disease

  This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.

  Recruiting Phase 2 Verve Therapeutics, Inc. · DeSoto, Texas · NCT07839936

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• Improving Care for underserved older Black patients with cardiovascular and other chronic conditions

  This study tests a culturally tailored approach to patient-centered care for older African American patients with cardiovascular disease and other conditions who receive care at a community hospital.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT07748858

• 4D MRI parameters linked to cardiovascular and cancer disease outcomes

  This study tests whether 4D MRI measurements can predict how cardiovascular diseases and cancer will progress in adults undergoing routine cardiac MRI at a single Korean hospital.

  Recruiting Ulsan University Hospital · Ulsan, Ulsan · NCT07678606

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.